放射性标记cCPE肽用于胰腺癌中claudin-4过表达的SPECT成像
紧密连接蛋白claudin-4在胰腺癌中过表达且与较好预后相关;本研究基于产气荚膜梭菌肠毒素C端(cCPE)晶体结构设计系列小分子突变体,经111In标记后在PSN-1细胞和荷瘤小鼠中评估亲和力与SPECT靶向能力。结果显示所有放射性偶联物在PSN-1细胞摄取显著高于HT1080阴性对照,亲和力较既往报道明显改善,[111In]In-cCPE194-319血清除快于[111In]In-cCPE.GST(半衰期<1分钟),注射后90分钟所有放射性肽在PSN-1荷瘤鼠中摄取显著高于HT1080荷瘤鼠。
要点
- 所有cCPE突变体放射性偶联物在PSN-1细胞摄取显著高于HT1080阴性对照。
- 所有肽的claudin-4亲和力较既往报道值明显改善,解离常数2.2±0.8至10±0.9 nM。
- 注射后90分钟所有放射性肽在PSN-1荷瘤鼠中摄取显著高于HT1080荷瘤鼠。
核心结论
- 这些优化的cCPE基SPECT显像剂作为claudin-4靶向载体用于胰腺癌claudin-4过表达体内显像展现出很大前景。
研究设计与样本
- 基于cCPE晶体结构,通过定点诱变生成一系列较小的cCPE194-319突变体,经马来酰亚胺-二乙烯三胺五乙酸定点偶联于C端半胱氨酸后以111In标记。
- 在表达claudin-4的PSN-1细胞及HT1080阴性对照中评估所有放射性偶联物的结合亲和力,在稳定转染claudin-4的HT1080细胞中评估所有cCPE突变体对claudin-4的特异性。
- 对荷PSN-1或HT1080肿瘤异种移植物的BALB/c裸鼠进行SPECT/CT显像,以确定这些肽的体内claudin-4靶向能力。
主要发现
- 所有cCPE基放射性偶联物在PSN-1细胞中的摄取显著高于HT1080阴性对照。
- 所有肽对claudin-4的体外亲和力较既往报道值明显改善,解离常数分别为2.2±0.8、3±0.1、4.2±0.5、10±0.9和9.7±0.7 nM。
- SPECT测得[111In]In-cCPE194-319的血清除明显快于[111In]In-cCPE.GST(半衰期<1分钟)。
- 注射示踪剂后90分钟,所有放射性肽在PSN-1异种移植物中的蓄积显著高于HT1080肿瘤:[111In]In-cCPE194-319为2.7±0.8 vs. 0.4±0.1 %ID/g(P<0.001);[111In]In-S313A为2.3±0.9 vs. 0.5±0.1 %ID/g(P<0.01);[111In]In-S307A+N309A+S313A为2±0.4 vs. 0.3±0.1 %ID/g(P<0.01);[111In]In-D284A为2±0.2 vs. 0.7±0.1 %ID/g(P<0.05);[111In]In-L254F+K257D为6.3±0.9 vs. 0.7±0.2 %ID/g(P<0.001)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Overexpression of tight-junction protein claudin-4 has been detected in primary and metastatic pancreatic cancer tissue and is associated with better prognosis in patients. Noninvasive measurement of claudin-4 expression by imaging methods could provide a means for accelerating detection and stratifying patients into risk groups. Clostridium perfringens enterotoxin (CPE) is a natural ligand for claudin-4 and holds potential as a targeting vector for molecular imaging of claudin-4 overexpression. A glutathione S-transferases (GST)-tagged version of the C terminus of CPE (cCPE) was previously used to delineate claudin-4 overexpression by SPECT but showed modest binding affinity and slow blood clearance in vivo. Methods: On the basis of the crystal structure of cCPE, a series of smaller cCPE194-319 mutants with putatively improved binding affinity for claudin-4 was generated by site-directed mutagenesis. All peptides were conjugated site-specifically on a C-terminal cysteine using maleimide-diethylenetriamine pentaacetate to enable radiolabeling with 111In. The binding affinity of all radioconjugates was evaluated in claudin-4-expressing PSN-1 cells and HT1080-negative controls. The specificity of all cCPE mutants to claudin-4 was assessed in HT1080 cells stably transfected with claudin-4. SPECT/CT imaging of BALB/c nude mice bearing PSN-1 or HT1080 tumor xenografts was performed to determine the claudin-4-targeting ability of these peptides in vivo. Results: Uptake of all cCPE-based radioconjugates was significantly higher in PSN-1 cells than in HT1080-negative controls. All peptides showed a marked improvement in affinity for claudin-4 in vitro when compared with previously reported values (dissociation constant: 2.2 ± 0.8, 3 ± 0.1, 4.2 ± 0.5, 10 ± 0.9, and 9.7 ± 0.7 nM). Blood clearance of [111In]In-cCPE194-319, as measured by SPECT, was considerably faster than that of [111In]In-cCPE.GST (half-life, <1 min). All radiopeptides showed significantly higher accumulation in PSN-1 xenografts than in HT1080 tumors at 90 min after injection of the tracer ([111In]In-cCPE194-319, 2.7 ± 0.8 vs. 0.4 ± 0.1 percentage injected dose per gram [%ID/g], P < 0.001; [111In]In-S313A, 2.3 ± 0.9 vs. 0.5 ± 0.1 %ID/g, P < 0.01; [111In]In-S307A + N309A + S313A, 2 ± 0.4 vs. 0.3 ± 0.1 %ID/g, P < 0.01; [111In]In-D284A, 2 ± 0.2 vs. 0.7 ± 0.1 %ID/g, P < 0.05; [111In]In-L254F + K257D, 6.3 ± 0.9 vs. 0.7 ± 0.2 %ID/g, P < 0.001). Conclusion: These optimized cCPE-based SPECT imaging agents show great promise as claudin-4-targeting vectors for in vivo imaging of claudin-4 overexpression in pancreatic cancer.
引用
- Torres JB, Mosley M, Koustoulidou S, et al. Radiolabeled cCPE Peptides for SPECT Imaging of Claudin-4 Overexpression in Pancreatic Cancer. J Nucl Med. 2020. PMID: 32414951. doi:10.2967/jnumed.120.243113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。